#1 Clinical Trials Search in Europe

Autologous Bone Marrow-Derived Adult Mononuclear Cells, Not Expanded

This article discusses the use of Autologous Bone Marrow-Derived Adult Mononuclear Cells, Not Expanded, in clinical trials for treating dilated cardiomyopathy. This innovative approach involves using a patient’s own bone marrow cells to potentially improve heart function in those suffering from this serious cardiac condition. We’ll explore the details of a specific clinical trial, its objectives, and what this could mean for patients with dilated cardiomyopathy.

Table of Contents

What is Autologous Bone Marrow-Derived Adult Mononuclear Cells Treatment?

Autologous Bone Marrow-Derived Adult Mononuclear Cells (BMMNCs) is an advanced therapy medicinal product. It’s a type of cell therapy where cells are taken from a patient’s own bone marrow, processed, and then given back to the same patient[1]. The term “autologous” means the cells come from the patient’s own body, reducing the risk of rejection.

This treatment is administered as a suspension for injection, which means the cells are suspended in a liquid that can be injected into the body. In the case of heart conditions, it’s given through intracoronary use, meaning it’s injected directly into the coronary arteries that supply blood to the heart[1].

What Medical Conditions Does It Treat?

The primary focus of current research with this treatment is on idiopathic dilated cardiomyopathy[1]. Let’s break down what this means:

  • Cardiomyopathy: This is a group of diseases that affect the heart muscle.
  • Dilated: In this type of cardiomyopathy, the heart chambers become enlarged or dilated.
  • Idiopathic: This means the cause of the condition is unknown.

Idiopathic dilated cardiomyopathy can lead to heart failure, a condition where the heart can’t pump blood effectively to meet the body’s needs[1].

How Does the Treatment Work?

The treatment involves injecting the patient’s own bone marrow cells directly into the coronary arteries of the heart. The goal is to improve the function of the heart in patients with dilated cardiomyopathy[1].

Scientists believe these cells may help in several ways:

  • They might help repair damaged heart tissue.
  • They could promote the growth of new blood vessels in the heart.
  • They may stimulate the heart’s own repair mechanisms.

However, it’s important to note that this is still an experimental treatment, and more research is needed to fully understand how it works and how effective it is[1].

Current Clinical Trial

A Phase IIb clinical trial is currently underway to evaluate the effectiveness of this treatment[1]. Here are some key points about the trial:

  • It’s a multicenter trial, meaning it’s being conducted at multiple hospitals or medical centers.
  • It’s double-blind and placebo-controlled, which means neither the patients nor the doctors know who is receiving the real treatment and who is receiving a placebo. This helps ensure the results are not biased.
  • The main objective is to see if the treatment can improve heart function in patients with idiopathic dilated cardiomyopathy[1].

Who is Eligible for the Treatment?

The clinical trial has specific criteria for who can participate. Here are some of the key eligibility requirements:

  • Patients must be between 18 and 70 years old[1].
  • They must have been diagnosed with idiopathic dilated cardiomyopathy for at least 6 months[1].
  • Their heart’s pumping ability (measured as left ventricular ejection fraction or LVEF) must be less than 40%, or between 40-50% if the heart is significantly enlarged[1].
  • Patients must have been on stable heart failure medication for at least 6 months[1].

There are also several conditions that would exclude a patient from participating, such as having certain other heart conditions, infections, or other serious diseases[1].

How is the Effectiveness Measured?

The researchers are using several methods to determine if the treatment is effective:

  • Changes in heart function as measured by special heart tests[1].
  • Improvements in symptoms and the patient’s ability to perform daily activities[1].
  • Changes in levels of certain proteins in the blood that indicate heart health[1].
  • The occurrence of major cardiac events like severe irregular heartbeats, hospitalizations, or need for a heart transplant[1].

Safety Considerations

Safety is a crucial aspect of any medical treatment. In this clinical trial, researchers are closely monitoring for any side effects or complications. They’re looking at:

  • Any adverse events that occur during or after the treatment[1].
  • Results of blood tests to check for any concerning changes[1].
  • Tests on the cell product itself to ensure it’s free from contamination[1].

It’s important to remember that while this treatment shows promise, it’s still in the research phase. Patients should always discuss their options with their healthcare provider to determine the best course of treatment for their individual situation.

Aspect Details
Study Type Phase IIb multicenter, double-blind, randomized, placebo-controlled trial
Treatment Intracoronary infusion of autologous adult mononuclear bone marrow cells
Target Condition Idiopathic dilated cardiomyopathy with heart failure
Primary Objective Evaluate efficacy in improving ventricular function
Key Inclusion Criteria Age 18-70, LVEF <40% or 40-50% with specific conditions, stable medical therapy for 6 months
Key Exclusion Criteria Secondary dilated cardiomyopathy, positive serology for HBV/HCV/HIV, recent myocarditis
Primary Endpoint Changes in ventricular function determined angiographically
Secondary Endpoints Clinical evaluation, BNP levels, echocardiogram results, exercise capacity, major cardiac events
Safety Monitoring Adverse events, laboratory determinations including microbiological cultivation

FAQ

  • What is the purpose of this clinical trial? The main purpose of this clinical trial is to evaluate how effective intracoronary injection of autologous bone marrow mononucleated cells (BMMNCs) is in improving heart function in patients with idiopathic dilated cardiomyopathy, a condition for which there is currently no effective treatment.
  • Who can participate in this clinical trial? Participants must be between 18 and 70 years old, diagnosed with idiopathic dilated cardiomyopathy for at least 6 months, have a left ventricular ejection fraction (LVEF) below 40% (or 40-50% with specific conditions), and meet other criteria. However, there are also several exclusion criteria, such as having secondary dilated cardiomyopathy or certain other medical conditions.
  • What does the treatment involve? The treatment involves collecting the patient's own bone marrow cells, processing them to isolate the mononuclear cells, and then injecting these cells into the coronary arteries of the heart. This is done to potentially improve heart function in patients with dilated cardiomyopathy.
  • What are the main outcomes being measured in this trial? The primary outcome is changes in ventricular function as determined by angiography. Secondary outcomes include changes in clinical status, heart function tests, exercise capacity, and the occurrence of major cardiac events during follow-up.
  • Is this treatment considered safe? While safety is one of the aspects being studied in this trial, previous studies have shown promise regarding the safety of this approach. The trial includes careful monitoring of adverse events and various laboratory tests to ensure patient safety throughout the study.

Ongoing Clinical Trials on Autologous Bone Marrow-Derived Adult Mononuclear Cells, Not Expanded

  • Study on the Effectiveness of Autologous Bone Marrow Cells for Patients with Dilated Cardiomyopathy and Heart Failure

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Autologous: Derived from the same individual. In this context, it means using the patient's own cells for treatment.
  • Bone Marrow-Derived Adult Mononuclear Cells: A type of cell found in bone marrow that includes stem cells and other cell types, which have the potential to aid in tissue repair and regeneration.
  • Dilated Cardiomyopathy: A condition where the heart becomes enlarged and cannot pump blood efficiently, often leading to heart failure.
  • Intracoronary Infusion: The process of delivering a substance directly into the coronary arteries of the heart.
  • Left Ventricular Ejection Fraction (LVEF): A measurement of how much blood the left ventricle pumps out with each contraction, used to assess heart function.
  • Angiography: An imaging technique used to visualize the inside of blood vessels and organs of the body, particularly the arteries, veins, and heart chambers.
  • BNP (Brain Natriuretic Peptide): A hormone released by the heart in response to changes in pressure that occur with heart failure.
  • NYHA Functional Class: A classification system used to indicate the extent of heart failure, based on how much the patient is limited during physical activity.
  • MACE (Major Adverse Cardiac Events): A composite endpoint in cardiovascular research that typically includes death, myocardial infarction, and stroke.
  • Advanced Therapy Medicinal Product: A class of innovative therapeutic products based on genes, cells, or tissues, which offers groundbreaking new opportunities for the treatment of diseases and injuries.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-autologous-bone-marrow-cells-for-patients-with-dilated-cardiomyopathy-and-heart-failure/